IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy
Top Cited Papers
Open Access
- 1 June 2008
- journal article
- Published by American Society of Hematology in Blood
- Vol. 111 (11) , 5326-5333
- https://doi.org/10.1182/blood-2007-09-113050
Abstract
IL-2 and IL-21 are closely related cytokines that might have arisen by gene duplication. Both cytokines promote the function of effector CD8+ T cells, but their distinct effects on antigen-driven differentiation of naive CD8+ T cells into effector CD8+ T cells are not clearly understood. We found that antigen-induced expression of Eomesodermin (Eomes) and maturation of naive CD8+ T cells into granzyme B- and CD44-expressing effector CD8+ T cells was enhanced by IL-2, but, unexpectedly, suppressed by IL-21. Furthermore, IL-21 repressed expression of IL-2Ra and inhibited IL-2–mediated acquisition of a cytolytic CD8+ T-cell phenotype. Despite its inhibitory effects, IL-21 did not induce anergy, but instead potently enhanced the capacity of cells to mediate tumor regression upon adoptive transfer. In contrast, IL-2 impaired the subsequent antitumor function of transferred cells. Gene expression studies revealed a distinct IL-21 program that was characterized phenotypically by increased expression of L-selectin and functionally by enhanced antitumor immunity that was not reversed by secondary in vitro stimulation with antigen and IL-2. Thus, the efficacy of CD8+ T cells for adoptive immunotherapy can be influenced by opposing differentiation programs conferred by IL-2 and IL-21, a finding with important implications for the development of cellular cancer therapies.Keywords
This publication has 64 references indexed in Scilit:
- Adoptive T cell therapy for cancer in the clinicJournal of Clinical Investigation, 2007
- Principles of adoptive T cell cancer therapyJournal of Clinical Investigation, 2007
- Persistence of Tumor Infiltrating Lymphocytes in Adoptive Immunotherapy Correlates With Telomere LengthJournal of Immunotherapy, 2007
- A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian CancerClinical Cancer Research, 2006
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine designNature Reviews Immunology, 2006
- Programming CD8+ T cells for effective immunotherapyCurrent Opinion in Immunology, 2006
- Adoptive immunotherapy for cancer: building on successNature Reviews Immunology, 2006
- Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiationNature Reviews Immunology, 2005
- Two subsets of memory T lymphocytes with distinct homing potentials and effector functionsNature, 1999